Noah L. Rosenberg's most recent trade in Verrica Pharmaceuticals Inc was a trade of 325,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on March 24, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Verrica Pharmaceuticals Inc | Noah L. Rosenberg | CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 325,000 | 325,000 | - | - | Employee Stock Option (right to buy) | |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2021 | 4,500 | 49,021 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.12 per share. | 13 Aug 2021 | 1,407 | 47,614 (0%) | 0% | 17.1 | 24,085 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.81 per share. | 28 Jul 2021 | 1,250 | 44,521 (0%) | 0% | 13.8 | 17,263 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.46 per share. | 11 May 2021 | 375 | 45,594 (0%) | 0% | 19.5 | 7,298 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.14 per share. | 11 May 2021 | 375 | 45,969 (0%) | 0% | 19.1 | 7,178 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.41 per share. | 05 Feb 2021 | 1,125 | 47,469 (0%) | 0% | 31.4 | 35,336 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.58 per share. | 05 Feb 2021 | 1,125 | 46,344 (0%) | 0% | 31.6 | 35,528 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Feb 2021 | 4,500 | 48,594 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 1,250 | 44,657 (0%) | 0% | 28.9 | 36,138 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.91 per share. | 03 Feb 2021 | 563 | 44,094 (0%) | 0% | 28.9 | 16,276 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2021 | 5,000 | 47,720 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 1,250 | 46,470 (0%) | 0% | 30.8 | 38,438 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.75 per share. | 31 Jan 2021 | 563 | 45,907 (0%) | 0% | 30.7 | 17,312 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 57,500 | 57,500 | - | - | Employee stock option (right to buy) | |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jan 2021 | 15,000 | 42,720 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.48 per share. | 23 Sep 2020 | 750 | 27,555 (0%) | 0% | 18.5 | 13,860 | Common Stock |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Sep 2020 | 3,000 | 29,055 (0%) | 0% | 0 | Common Stock | |
| Travere Therapeutics Inc | Noah L. Rosenberg | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.59 per share. | 18 Sep 2020 | 750 | 28,305 (0%) | 0% | 18.6 | 13,943 | Common Stock |